Litcius/Paper detail

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021

Shaun J. Grannis, Elizabeth Rowley, Toan C. Ong, Edward Stenehjem, Nicola P. Klein, Malini B. DeSilva, Allison L. Naleway, Karthik Natarajan, Mark G. Thompson, VISION Network

2021MMWR Morbidity and Mortality Weekly Report156 citationsDOIOpen Access PDF

Abstract

Data on COVID-19 vaccine effectiveness (VE) since the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating strain in the United States are limited (1-3). CDC used the VISION Network* to examine medical encounters (32,867) from 187 hospitals and 221 emergency departments (EDs) and urgent care (UC) clinics across nine states during June-August 2021, beginning on the date the Delta variant accounted for >50% of sequenced isolates in each medical facility's state. VISION Network methods have been published (4).

Topics & Concepts

InterimCoronavirus disease 2019 (COVID-19)Emergency departmentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Medicine2019-20 coronavirus outbreakVirologyPandemicEmergency medicineDeltaMedical emergencyOutbreakInternal medicineGeographyInfectious disease (medical specialty)NursingAerospace engineeringDiseaseEngineeringArchaeologySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 epidemiological studies